Skip to main content
Premium Trial:

Request an Annual Quote

Roche's Dreismann Lands on Nanogen's Board; Digene Names New R&D VP; Open Biosystems Hires S&M VP; and Others

NEW YORK (GenomeWeb News) — Heiner Dreismann has been named to the board of directors at Nanogen, the company said this week.
 
Dreismann is the current CEO of FasTraQ and previously served as president and CEO of Roche Molecular Systems
 
Dreismann became a director of Iconix Biosciences last week and last month became a director of GeneNews, formerly ChondroGene.

 
Open Biosystems has named Ray “Woody” Woodward its new vice president of sales and marketing. Woodward is former North American general manager for Miltenyi Biotec.
 
Open Biosystems, which makes genomics research tools, said Woodward’s 30 years of experience marketing in the medical device industry will be an asset as they market RNAi interference and genomics technology.

 
Avalon Pharmaceuticals has appointed Todd Golub as chairman of the company’s scientific advisory board, the company said today.
 
Avalon is a Germantown, Md.-based developer of small molecule therapeutics based on large-scale gene expression analysis.
 
Golub is a founding member of the Broad Institute at MIT, a former director of cancer genomics at the Whitehead/MIT Center for Genomics Research, and has specialized in the application of genomic tools to the classification and study of cancers, and has made ‘fundamental discoveries’ in the field of childhood leukemia.

 
Microchip Biotechnologies, an early-stage company developing nanofluidic sample preparation and analysis tools, today said it has named David Barker and Mostafa Ronaghi to its board of directors.
 
Barker is vice president and chief scientific officer of Illumina. Ronaghi is the co-founder of several biotech companies, including Pyrosequencing, ParAllele Biosciences, and NextBio. He is currently a principal investigator at the Stanford University Genome Center.

The University of Miami’s Miller School of Medicine this week said it is hiring two top Duke University genomics and genetics researchers to head their planned Institute of Human Genomics:
 
Margaret Pericak-Vance is currently director of Duke University’s Center for Human Genetics, James B. Duke professor of medicine, and chief of medical genetics at Duke Medical Center.
 
Jeffrey Vance is currently associate director of the Duke Center for Human Genetics, professor of medicine, and director of Duke’s Parkinson’s Disease Research Center.   

 
Digene has named James Godsey to be vice president of research and development.
 
Godsey comes to Digene from Veridex, a Johnson & Johnson diagnostics and genomics company, where he was vice president of R&D.

 
CytRx CEO Steven Kriegsman received the Lou Gehrig Memorial Award from the Muscular Dystrophy Association, the biopharmaceutical firm said this week.
 
The award was given at an annual gala that raises funds for the MDA for ALS research.
 
CytRx is currently conducting second phase safety studies of a drug, arimoclomol, designed to treat amyotrophic lateral sclerosis.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.